




Healthcare Industry News: Regenesis Biomedical
News Release - January 16, 2012
Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
New leadership role as the company expands market reachSCOTTSDALE, Ariz., Jan. 16, 2012 -- (Healthcare Sales & Marketing Network) -- Regenesis Biomedical, Inc., a medical technology company that markets the ProvantŪ Therapy System, announced today that Scott Brooks has joined the company in the newly created position of Chief Operating Officer. Scott is responsible for helping scale the organization's capabilities to support increased market penetration and broadened reimbursement.
"Scott is a mission focused, strategic, and process minded leader with experience scaling an organization," said Virginia Rybski, President and CEO of Regenesis. "We look forward to his contributions in building upon our performance based culture."
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.
About the ProvantŪ Therapy System
Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.
Source: Regenesis Biomedical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.